ErVimmune

https://ervimmune.com/

Background

ErVimmune is a French biotechnology company, founded in October 2019, specializing in revolutionary cancer vaccines and T cell-based therapies. They focus on targeting non-conventional tumor antigens derived from human endogenous retroviruses (HERVs) to address unmet medical needs in “cold tumors.” The company leverages a proprietary, AI-driven platform for target discovery and is a spin-off of Centre Leon Berard (CLB).